The idiopathic inflammatory myopathies (IIM ) are syscurrent knowledge of molecular mechanisms believed to be of importance in these disorders [16, 17] . temic connective tissue diseases which are characterized by symmetrical, proximal muscle weakness, decreased muscle endurance and chronic inflammation in muscle
The pathophysiological basis for treatment of tissue [1] [2] [3] . They can be subclassified into dermato-IIM myositis, polymyositis and inclusion body myositis (IBM ) according to differences in clinical as well as
The primary aim for treatment of myositis is to improve histopathological features [1, 4] . Dermatomyositis may muscle function. The molecular background of muscle occur in both adults and children; in this review, we weakness in myositis is currently largely unknown. There will, however, focus on the treatment of adult forms of is a lack of correlation between the extent of muscle myositis only. Myositis may exist as a disease entity on weakness and degree of muscle inflammation as assessed its own or may be linked to another inflammatory by the presence of inflammatory cell infiltrates in muscle connective tissue disease such as systemic sclerosis or tissue or serum levels of muscle enzymes [18, 19] . In mixed connective tissue disease. Myositis may also be some cases, there is no detectable infiltrate of inflamassociated with a malignancy, this is particularly true matory cells despite muscle weakness and this is particufor dermatomyositis, but the association with polymyolarly common in dermatomyositis and IBM [20, 21] . sitis is more controversial [1] . The IIM are chronic Furthermore, patients with polymyositis and dermatodisorders in most cases and up to two-thirds of patients myositis often continue to exhibit reduced muscle develop residual functional impairment [5] [6] [7] . Several strength, even after intense immunosuppressive treatimmunosuppressive treatments are available for ment and subsequent disappearance of inflammatory inflammatory myopathies, yet for many patients recovinfiltrates [18, 22] . Efforts to date have also been unsucery is incomplete [5, 8] . Life-long immunosuppressive cessful in the identification of other morphological therapy is often required, adverse side-effects are changes, such as muscle atrophy or replacement of common and more effective therapies with fewer sidemuscle tissue by fat, which may be responsible for effects are needed [9] . During the last few years, publicapersistent muscle weakness [22] . Based on these observations of treatments have been dominated by a number tions, it is likely that factors other than the inflammatory of comprehensive review articles, but very few new process per se are involved in the mechanisms causing therapeutic trials have been reported [8, [10] [11] [12] [13] [14] [15] . This muscle weakness. This hypothesis is further supported review will discuss the currently recommended treatment by metabolic abnormalities such as reduced levels of modalities in adult IIM and summarize recently pubphosphocreatine (PCr) and adenosine triphosphate lished therapeutic studies mainly focused on cyclosporin (ATP), as detected by magnetic resonance spectroscopy A, i.v. immunoglobulin (IVIg) and on non-pharma-(MRS), indicating defective energy metabolism in both cological treatment through physical exercise. We also dermatomyositis and polymyositis cases [23] [24] [25] . wanted to focus on investigations that could be perFrom the preceding discussion, it is clear that a better formed to assess the effect of treatment, and finally to understanding of basic pathophysiological mechanisms discuss the possibilities of new treatments based on is needed in order to improve the treatment of these conditions. One way of contributing to such knowledge is obviously to include pathophysiologically directed investigations in longitudinal clinical studies of myositis.
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muscle strength and endurance, as well as molecular and untreated myositis patients [35, 37] , even though a higher mortality rate was reported in myositis before studies on repeated muscle biopsies and repeated MRS investigations. Very few studies have actually assessed the corticosteroid era [38, 39] . These discrepancies in outcome mainly emphasize the limitation of retrospectthe effect of a given therapy on muscle inflammation by investigating the histology of repeated muscle biopsies ive studies, in which patient groups are not always well defined, and treatment and assessment methods are not and correlated these findings to muscle function [18, 26 ] . Thus, the molecular effect on muscle inflammation standardized. Given the fact that no placebo-controlled trials with of most immunosuppressive drugs used today is largely unknown. Until such studies have been undertaken, we the use of corticosteroids have been performed, our interpretation of existing data is that a starting dose of can only adhere to the currently recommended treatments for IIM, which are largely based on uncontrolled prednisone of 0.75 mg/kg/day (which corresponds to 40-60 mg/day) is likely to suffice in most myositis studies with assessment of clinical and/or biochemical outcome. Furthermore, these studies are limited by the patients. No data on outcome have been published to support the often recommended dose of 1-2 mg/kg/day fact that several different tests of muscle function and strength have been used, which makes comparisons of (or 80-100 mg/day) for 4-12 weeks [1, 3, 8, 10] as favourable compared to doses of 40-60 mg/day. We the outcome between different studies problematic [5, [26] [27] [28] [29] [30] .
would also recommend that the initial high dose of corticosteroids is maintained for 4-12 weeks; this recommendation is based on the observation of a maximal improvement after a mean of 12 weeks [5, 29, 40, 41] .
Pharmacological therapy
Reduction of the corticosteroid dosage should be guided Corticosteroids by improved muscle function [1, 2, 15, 27]. We suggest that tapering of corticosteroid dosages should be initially The general recommended treatment of IIM consists of corticosteroids in high doses for the initial few months, conducted in small decrements of~20% of the daily dosage per month and that tapering could be started with or without other immunosuppressive therapies [1, 8, 11, 15] . Placebo-controlled trials of corticosteroid when a normal or close to normal muscle function has been achieved, regardless of persisting elevated creatine treatment have never been performed and the optimal initial dosage of corticosteroids, as well as duration of phosphokinase (CPK ) levels. Corticosteroid treatment in consolidation dosages of 5-15 mg/day is often treatment, is therefore uncertain. The only prospective study of corticosteroids found in a literature survey was required for several years. A mean duration of treatment of 3 yr was observed in one study, and although some one in which the effect of prednisone alone was compared to the effect of prednisone together with azapatients still had relapses upon withdrawal of corticosteroids, a gradual tapering of the corticosteroids to thioprine. Eight patients with polymyositis received 60 mg/day of prednisone as a starting dose and six out withdrawal should be attempted anyway after 2-3 yr [28] . of eight acquired improved muscle function after 3 yr, although none recovered normal muscle function [31] .
Other immunosuppressive treatment In retrospective studies, improved muscle function was observed with an initial dose corresponding to Although most patients with poly-and dermatomyositis respond, at least partially, to corticosteroids,~30% of prednisone 40-60 mg/day in 60-80% of the patients assessed by the manual muscle test (MMT ) or by one patients do not respond at all [5] . Moreover, in a longterm follow-up study, a substantial number of patients of several muscle function scales [5, 27-29, 32, 33] . It is noteworthy that although a majority of patients developed increased disability over time due to sideeffects of the corticosteroid treatment [9] . These observaimproved, a complete recovery rate was reported in only 24-43%. The duration of the high prednisone dose tions emphasize the need for improved treatment for patients with IIM. Several immunosuppressive agents (Á40 mg/day) in these studies varied between 4 days and 9 weeks [5, 20, 28, 33] . In the retrospective study have been reported both as steroid-sparing agents as well as beneficial in patients who are steroid resistant, of Henriksson and Sandstedt [5] , a significant correlation was determined between the degree of functional but few controlled therapeutic trials have been performed. Azathioprine was reported to have a steroidimprovement using a four-graded score and a mean total dose of at least 0.5 mg/kg/day during the first sparing effect as well as a favourable effect on clinical function compared to prednisone alone in a placebo-3 months compared to 0.3 mg/kg/day. In a more recent retrospective study, a clinical response rate of 86% was controlled trial [31] . Notably, the effect on muscle function was significant not at the 3 month follow-up recorded after an initial dose of Á0.75 mg/kg/day [30] . In two other retrospective studies, a spontaneous of the blind study, but after 1 and 3 yr and when the code had been broken, and the steroid-sparing effect response rate of 50% was reported [34, 35] , while in another small study the spontaneous response rate was 0 was not significant until after 3 yr [18, 31] . The lack of difference in muscle strength, as measured by MMT, [27] . In retrospective studies in which survival rate was used as an outcome measure, no difference was after 3 months is not surprising as the patients were given the same corticosteroid dose during this first part evident between low-dose (<10 mg/day) and high-dose (Á20 mg/day) corticosteroids [36 ] , or between treated of the study and 3 months is far too short a time to expect the full effect of the immunosuppressive treatment [5] . It is more remarkable that there was significantly less functional disability after 12 months treatment as assessed by the relatively crude functional disability index and considering the low number of patients in each group. In another placebo-controlled trial, IVIg was beneficial in treatment-resistant dermatomyositis patients both on muscle function and on muscle histopathology [26 ] . Adding plasmapheresis had no positive effect compared to corticosteroids alone in a third controlled trial [42] . A combination of oral methotrexate with azathioprine may be of benefit to treatmentresistant poly-and dermatomyositis cases according to a recently published controlled trial [43] . However, the study lacked power to compare the two treatment regimens directly, the other treatment being i.v. methotrexate with leucovorin rescue, which may also benefit some patients with refractory myositis [43] . In addition to these controlled trials, open studies and case reports indicate a positive effect of methotrexate on muscle function in steroid-resistant cases [44, 45] . The doses of methotrexate have varied between 7.5 and 25 mg/week administered orally or i.m., or up to 100 mg/week i.v. [44, 45] .
In an additional open retrospective study, male myositis patients with Jo-1 antibodies with incomplete clinical response to corticosteroids were reported to have a more favourable clinical response to additional treatment with methotrexate compared to azathioprine [30] . The effect of cyclophosphamide in IIM is more controversial. In one open study, some patients were reported to benefit from daily oral cyclophosphamide [46 ] , even though i.v. pulse cyclophosphamide was reported to be ineffective in another open study [47] . Chlorambucil had a beneficial effect in a few treatment-resistant dermatomyositis cases [48] . During recent years, cyclosporin A has been relatively widely used in juvenile dermatomyositis [49] [50] [51] [52] . In adult myositis, there are only a few reports on the beneficial effects of cyclosporin A, mainly in treatment-resistant polyand dermatomyositis cases (Table 1) [53] [54] [55] [56] [57] . Notably, the effect is often evident within a few weeks of treatment. In one open study of adult dermatomyositis, cyclosporin A was reported to be beneficial as a firstline drug without corticosteroids [58] .
Finally, in addition to the above-mentioned controlled trial of IVIg in polymyositis and dermatomyositis, a few open studies have been presented. In one such study, IVIg as an initial treatment without corticosteroids was insufficient to suppress disease activity in patients with polymyositis and dermatomyositis [59] . In another open study, IVIg was beneficial on muscle strength, function and muscle enzyme levels in a few treatment-resistant cases with dermatomyositis or polymyositis, but not in patients with IBM [60] . From the studies on IVIg treatment in poly-and dermatomyositis undertaken so far, one can conclude that treatment-resistant cases with dermatomyositis could benefit from IVIg infusions, but further studies are needed to clarify the effect in patients DM, dermatomyositis; JDM, juvenile dermatomyositis; PM, polymyositis; ILD, interstitial lung disease; HT, hypertension; n.a., no available information; renal imp = renal impairment.
aCyclosporin A was used as a first-line drug in this study.
with polymyositis. However, IVIg does not cure patients with dermatomyositis as a prolonged time of infusions high risk of corticosteroid-related side-effects and the risk of non-responsiveness to corticosteroid treatment is required [26 ] .
Treatment of IBM necessitates a separate discussion. alone. According to the data mentioned above, azathioprine should be the first choice as a steroid-saving drug. This entity was first identified as treatment-resistant polymyositis [61] and was followed by other case reports Although methotrexate is often used in clinical practice, the efficacy of this drug in IIM still needs to be evaluated on myositis patients being refractory to corticosteroid treatment and with a corresponding histopathology in a controlled trial. The data are less clear regarding the beneficial effect of adding cyclophosphamide, cyclo- [62] [63] [64] . Only a few therapeutic trials including IBM patients have been reported on in the literature. In three sporin A, IVIg or chlorambucil compared to corticosteroids alone, and more controlled trials are necessary retrospective studies,~50% of IBM patients responded to corticosteroids with temporarily or partially improved before general therapeutic recommendations can be made. muscle function, but none recovered completely; some improved on methotrexate, but none had a complete response [30, 65, 66 ] . In a prospective trial, 2/9 patients Non-pharmacological therapy improved regarding muscle function after combination therapy with methotrexate and azathioprine, and 4/9
Despite the pronounced functional deficit in patients with myositis, the non-pharmacological interventions had a stabilization of disease progress [66 ] . In the same study, i.v. methotrexate (0.5 g/m2 every 2 weeks) with have received little attention. An important but controversial treatment of IIM is physical exercise. Because of leucovorin rescue resulted in improved muscle function in 1/10 cases and stabilization of disease progress in fear of causing disease flare-ups, patients with myositis have been recommended to avoid active exercise. Recent 7/10 [66 ] . In a recently published placebo-controlled study, functionally important improvement of muscle studies, however, have demonstrated that active exercise could be safely performed in patients with chronic, function was observed in 6/19 patients after a 3 month trial with IVIg, but there was no significant difference stable poly-and dermatomyositis without increased muscle inflammation assessed by CPK [71] or by muscle compared to the placebo group [67] . There were regional effects on certain muscle groups of the lower extremities biopsies and magnetic resonance imaging (MRI ) [72] , and with beneficial effect on muscle function. Beneficial and muscles controlling swallowing function; however, they were of unknown clinical significance. Half the effect on muscle strength after bicycle and step aerobic training for 6 weeks was reported in patients with patients chose to pursue the IVIg therapy because, according to their own assessment, it had made a chronic, inactive poly-and dermatomyositis in a recently published controlled study of 14 patients [73] . There is difference in their daily activities and quality of life [67] . In contrast, muscle strength was found to be worsened one report on exercise in IBM including five patients who gained increased muscle strength after 12 weeks of in all nine patients given IVIg in an open trial [68] . From these limited numbers of therapeutic trials hitherto progressive, resistive exercise without increased disease activity as assessed by CPK levels [74] . The effects of performed in IBM, it is still controversial whether immunosuppressive drugs have a beneficial effect in this exercise in addition to drug treatment in patients with active, recent-onset disease have only been investigated disease entity; some patients have a temporary or stabilizing effect on clinical symptoms, but so far there are in a limited number of patients so far, although with beneficial effect on muscle strength and function, and no reports on recovery of muscle function. This therapeutic problem also reflects the fact that the pathowithout signs of increased disease activity [75, 76 ] . Whether active physical exercise should be introduced physiology behind the clinical symptoms is even less well known for this subgroup of myositis than for polyduring the early stage of treatment to diminish the risk of persisting, chronic muscle weakness is still unclear and dermatomyositis, and there is still a debate about whether the inflammatory changes in muscle tissue are and can only be addressed by a controlled trial. The recommendation today is gradually to include active primary or secondary phenomena in IBM. Interestingly, persisting inflammation in muscle tissue was observed physical exercise when disease activity begins to regress; this exercise could include a light to moderate home after a median of 60 months of corticosteroid treatment in one study [69] . On the contrary, in another study, a exercise programme or a low-intensity aerobic programme on a cycle or in the pool [72, 77] . decreased cell infiltration was observed in muscle tissue after an average of 13.6 months of corticosteroid treatment, but still muscle function deteriorated [70] . These Investigations for assessment of treatment studies emphasize the need for more controlled trials including larger patient groups, as well as the need for Both for the physician who is going to monitor treatment for individual patients and for the purpose of assessing investigations on the effects of a given therapy both on muscle function and on the cellular and molecular events the effects of therapies in controlled trials, there is a need to measure disease activity and to distinguish in muscle tissue.
Our interpretation of these therapeutic reports in IIM disease activity from chronic, irreversible changes that cause disability. Currently used diagnostic toolsis that immunosuppressive drugs should be included from the start of therapy, as was previously advocated muscle biopsy, elevation of serum enzyme activity, such as CPK, and characteristic electromyography featuresby some authors [8] ; the reasons for this being both the have never been validated as follow-up measures and changes is low and has not been validated in follow-up studies; second, definition of improvement has never are hampered by various limitations [20, [78] [79] [80] [81] [82] [83] ( Table 2 ). The most often used assessments for therabeen agreed upon or validated; finally, it requires patient cooperation and is time consuming. A more sensitive peutic responses are clinical evaluation of muscle strength and serum muscle enzyme activity [5, 27, 29, technique to measure muscle strength is the modified sphygmomanometer, but its use is limited by the high 84]. Recently, MRI, MRS, muscle ultrasound and antimyosin scintigraphy have been introduced as possible interobserver variation [96 ] . A better interobserver reliability was observed with the use of a handheld pulltools for both diagnostic purposes and for assessment of disease activity [24, [85] [86] [87] [88] [89] [90] [91] [92] . Although there is a gauge, another tool to measure muscle strength; however, its usefulness in a longitudinal study has not been general agreement that muscle function is the most relevant factor for evaluating therapeutic responses, validated [97] . All these tests measure strength and not endurance; furthermore, the relevance of these tests to there is no consensus as to how this should be assessed. Moreover, as a reduction of muscle function could be the patients has not been validated. An isokinetic dynamometer is a sensitive tool to measure muscle the result of both active muscle inflammation and chronic fibrotic changes, the measurement of muscle strength as well as endurance, but is generally not available in a rheumatology practice and requires a function needs to be combined with one or several tools that could reflect active muscle inflammation. Thus, trained person to conduct the tests. A 'Timed-Stands' test, measuring the time needed to stand 10 times from there is a strong need for a standardized outcome measurement which reflects disease activity; such an a standard chair, was reported with good sensitivity to changes, but the major limitation is its confinement to activity index is currently being developed for juvenile dermatomyositis [93, 94] and it will be important to the lower extremities [98] . The Functional Index of Myositis [99] measures endurance and strength, and is develop a similar instrument for adults with myositis.
feasible to use in a follow-up study of exercise [72] . It requires a physiotherapist to perform the tests, but not Functional assessment any specialized equipment. However, for this test, we also determined a limitation in sensitivity to changes in Muscle weakness is a complex result of decreased strength and endurance which should be recognized those cases with a low degree of muscle weakness. Functional tests based on questionnaires have been used, when choosing a tool to measure muscle function. Many patients with myositis experience both impaired muscle but not validated among patients with IIM, neither have functional disability scales, and there is a lack of agreestrength and muscle endurance; however, some patients, particularly those who have partly recovered muscle ment upon a definition of improvement in these scales [5, 27, 28] . Thus, the Functional Index of Myositis [99] function during treatment, can often manage a strength test once or twice, but cannot do repeated tests or a is by our means the most useful and reliable functional test for clinical practice, but it still requires further longer exercise using the same muscle group. A test which measures muscle endurance is more sensitive and validation if it is to be used as a single test in therapeutic studies. is more likely to detect impaired muscle function than a strength test in this particular group of patients. Furthermore, the muscle tests should measure functions Laboratory investigations which are relevant to the patients. The most commonly used technique for assessing muscle function is the As muscle function alone does not discriminate between active and chronic disease, a combination with laborat-MMT with the MRC scale [95] . There are several drawbacks to this method: firstly, its sensitivity to ory investigations is required. Erythrocyte sedimentation T 2. Proposed revised criteria for the diagnosis of idiopathic inflammatory myopathies [80]a 1. Symmetricb, proximal muscle weakness 2.
Elevation of the serum levels of enzymes including not only CK levels, but also aldolase, AST, ALT and lactate dehydrogenase levels 3.
Abnormal electromyogram with myopathic motor unit potentials, fibrillations, positive sharp waves and increased insertional irritability 4.
Muscle biopsy features of inflammatory infiltration and either degeneration/regeneration or perifascicular atrophy 5.
Any of one of the myositis-specific autoantibodies (an antisynthetase, anti-Mi-2 or anti-SRP) 6.
Typical skin rash of DM that includes Gottron's sign, Gottron's papules or heliotrope rash ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase. aPossible idiopathic inflammatory myopathy (IIM ) = any two criteria; probable IIM = any three criteria; definite IIM = any four criteria. Results of magnetic resonance imaging that are consistent with muscle inflammation may be substituted for either criterion 1 or 2. Patients with IIM who satisfy criterion 6 may be subclassified as having dermatomyositis (DM ). Those who satisfy the proposed criteria for inclusion body myositis [6 ] may be subclassified as having inclusion body myositis. The application of these criteria assumes that known infectious, toxic, metabolic, dystrophic or endocrine myopathies have been excluded by appropriate evaluations. Criteria 1, 2, 3, 4 and 6 are the original Bohan and Peter criteria in similar form.
bSymmetry is intended to denote bilateral, but not necessarily equal, involvement.
rate and other acute-phase reactants are only elevated images were found using T1-weighted imaging [87, [110] [111] [112] [113] . In chronic polymyositis and dermatomyositis in a limited number of cases with IIM, and are hence not useful in assessment of disease activity [100] . There patients, muscular atrophy of variable distribution and fatty infiltration within the atrophied muscles were is also a limitation to the use of muscle enzymes such as CPK as the only measure of disease activity since in reported using a combination of T1-weighted and fatsuppressed MRI, and the elevated fatty replacement some myositis patients with active disease the level of CPK activity was normal [28, 29, 101] , and other correlated with the duration of the disease [25, 87, 112, 113, [116] [117] [118] [119] [120] . Fat-suppressed imaging is needed to patients have persistent elevated muscle enzyme without other signs of disease activity and normal muscle funcdifferentiate between fat and oedema, as fat gives rise to hyperintense signals in both T1-and T2-weighted tion [8] . Previous reports also indicated that serum CPK activity could be in the normal range even when abnorimages, and oedema may be masked by concurrent fatty changes. mal anatomical and biochemical changes were observed [29] , and in therapeutic trials laboratory responses MRI of muscles is also a feasible non-invasive assessment tool to use for follow-up studies as a strong including CPK, aldolase and lactate dehydrogenase (LD) levels were more common than improved muscle correlation was determined between increased T2 These studies have primarily focused on phosphorus MRS, which allows assessment of muscle bioenergetic good diagnostic yield and which can be performed with little discomfort for the patients, and which allow for metabolites such as PCr and ATP. In dermatomyositis cases with muscular symptoms, ATP and PCr levels repeated biopsies [104] . This semi-open biopsy technique can easily be performed by the rheumatologist in an were reduced, while the ratio of inorganic phosphate (Pi) to PCr (Pi/PCr) was increased relative to controls out-patient clinic with a very low complication rate, and could be included as a tool for assessment of disease even at rest. These metabolic abnormalities were further accentuated with exercise [23, 24, 113] . In amyopathic activity in clinical trials [105] . The problem with 'skip lesions' could be reduced by taking several biopsies from dermatomyositis, resting ATP and PCr levels and the Pi/PCr ratio were similar to controls, but during exercise the same incision [106 ] . Another way to overcome this problem is to use MRI to select an appropriate site for the Pi/PCr ratio was elevated with no significant ATP loss [122, 124] . Interestingly, these studies support the muscle to be biopsied [107, 108] . Further knowledge of disease pathogenesis and the effect of treatment at a hypothesis that metabolic disturbances are at least partly involved in the pathogenesis of the muscle weakness molecular level could be obtained by performing repeated muscle biopsies and by correlating histological and endorse the need for alternative therapies to the currently used immunosuppressives. Muscle bioenergetic findings to clinical outcome. defects preceded other changes and even persisted after Magnetic resonance imaging resolution of inflammation [24, 124] . Phosphorus MRS may thus have the potential to be used as a tool to MRI can be used to examine anatomical changes in diseased muscle non-invasively and to assess disease evaluate therapeutic regimens [24, 123, 125] . activity, but it cannot replace muscle biopsy for diaProton magnetic resonance spectroscopy gnostic evaluation. It may be more sensitive and specific than ultrasound for diagnosis of IIM, especially in cases Two studies have reported the use of proton MRS to assess patients with myositis. In a sequential report of in which muscle enzymes are normal [109] . The sensitivity and specificity of MRI in the diagnosis of myositis a juvenile dermatomyositis case, proton MRS determined an abnormally low lipid-to-water ratio at the are dependent on the technique employed; in muscle of acute polymyositis and dermatomyositis patients, onset of the disease and the latter ratio became abnormally high compared to controls at 3 months of treatoedema was observed using T2-weighted and/or short tau inversion recovery (STIR) imaging, whereas normal ment [126 ] . This observation may reflect oedema formation during onset of the disease, which diminished chronic disability and a reduced quality of life due to persisting decreased muscle function as well as to sideafter treatment (as confirmed by MRI ), and lipid deposition in muscle during chronic stages of the disease effects of corticosteroid treatment. Until more controlled trials have been performed, we mainly have to rely upon [126 ] . In another study, other muscle metabolite ratios, such as choline/lipid and creatine/lipid, were signifiinterpretations of uncontrolled trials for treatment recommendations for patients with IIM. These studies cantly different in chronic polymyositis and dermatomyositis cases compared to control subjects [25] . These support initial treatment with prednisone in starting doses of 0.75 mg/kg/day for~4 weeks with tapering abnormalities were evident in patients with normal as well as elevated CPK activities [25] . Further studies are doses according to muscle function thereafter. Because of the high corticosteroid doses that are required, an needed to determine whether proton spectroscopy is an appropriate tool for disease activity assessment.
additional steroid-saving immunosuppressive would be optimal and controlled trials are of great necessity. By Abnormal metabolic profiles were also recorded in the urinary proton MR spectra of IIM patients. Levels performing careful follow-up studies correlating clinical outcome with molecular findings in repeated muscle of the muscle metabolites, such as creatine, cholinecontaining compounds, glycine, taurine and betaine, biopsies and MRS, an increased knowledge concerning the pathogenesis as well as the effect of treatment at a were all significantly higher than in controls [127] . High levels of urinary creatine were recognized early in this molecular level will be achieved. An increased knowledge of which molecules, e.g. cytokines and chemokines, are disease using standard methods for many decades [27, 128] , but the widespread nature of other changes has important in the inflammatory process will hopefully make it possible to develop more selective therapies for not been previously reported. Elevated taurine levels in urine were also reported in other conditions, probably myositis patients, similar to the development of new treatment modalities which are currently being investireflecting general muscle degeneration [127] . Creatine, choline-containing compounds, glycine and taurine gated in rheumatoid arthritis [131] . A rarely recognized aspect of the IIM is the possible metabolic disturbance levels were reduced with treatment in polymyositis and dermatomyositis patients, and their levels seemed to be as a cause of the persisting muscle weakness. The use of MRS to assess metabolic molecules provides a promrelated to clinical outcome [127] . Urinary proton MRS metabolic profiles may thus have the potential to be a ising new means of disease activity assessment that needs to be further evaluated in follow-up studies. An importnon-invasive method for assessment of disease activity in IIM patients and to monitor the efficacy of therapy ant aspect of treatment that should be included in the rehabilitation programme of the IIM is active physical in an objective manner.
MRS (in particular phosphorus) in conjunction with exercise, which was recently demonstrated not only to be safe, but also to improve muscle strength in myositis MRI offers new avenues for assessing the biochemical status of diseased muscles in myositis patients. The patients [71] [72] [73] [74] [75] . To facilitate the development of improved therapies, a validated disease activity measure changes observed using MRI and spectroscopy were determined to be more reliable than the conventional would be very helpful. An international collaboration group could hopefully develop such a disease activity CPK activity, as abnormal anatomical and biochemical changes were often observed in clinically symptomatic index for adult myositis, encouraged by the work which has already started for juvenile dermatomyositis [94] . patients with normal CPK activities [25, 109, 114] . MRS together with MRI may have the potential to evaluate the biochemical and anatomical changes that are signifi-
